DERMATITIS, ATOPIC

This study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with DUPIXENT. Researchers will collect information on medical history, skin symptoms, and quality of life over time to see how well the drug works and how safe it is in eve…

This study tests an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for 12 weeks, and doctors m…

This study looks at the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive the drug for up to 5 years, with regular check-ups to monitor side effects and skin improv…

This study tests a new medicine, BAT6026, in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't been helped enough by creams or ointments. The goal is to see if the drug is safe and can reduce eczema symptoms, like redness and itching, by at least 75% after …

This study tests whether a monthly injection of amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. About 1,500 participants who already responded to the drug in earlier studies will either continue trea…

This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. The goal is to see if a new, less frequent dosing schedule (every 12 weeks) works as well as the current one (every 4 weeks) at controlling skin symptoms. Participants will r…

This study looks at how well dupilumab (Dupixent) works over 2 years in children aged 6 to 14 with moderate-to-severe atopic dermatitis (eczema). About 48 kids will receive the drug and have their skin barrier function measured. The goal is to see if long-term treatment improves …

This study looks at the long-term safety and effectiveness of amlitelimab, an injected drug for moderate to severe eczema (atopic dermatitis). It includes over 1,600 people who have already taken amlitelimab in earlier studies. Some participants will stop treatment temporarily to…

This study tests a new medicine called 611 in 124 children and teens (ages 6 to 17) with moderate to severe eczema. The goal is to see if it is safe and how well it works to reduce skin symptoms like redness and itching. Participants receive the drug as an injection, and research…

This study follows 262 people with moderate to severe atopic dermatitis (eczema) who previously received an experimental stem cell treatment called FURESTEM-AD. The goal is to check for any long-term side effects and see how well the treatment holds up over time. Participants are…